Key facts
- This page summarizes Merdad Parsey's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 9 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Nov 2024, 20:10.
Merdad Parsey - 27 Nov 2024 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- GILD
- Reported as of
- 27 Nov 2024
- Net transaction value
- -$6,014,325
- SEC form
- 4
- Accepted by SEC
- 29 Nov 2024, 20:10:23 UTC
- Prior SEC filing
- 07 Nov 2024
- Next SEC filing
- 11 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Kim by Power of Attorney for Merdad Parsey
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Merdad Parsey filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 29 Nov 2024.
Change
- Previous filing in this sequence was filed on 07 Nov 2024.
- Current net transaction value: -$6,014,325.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GILD
transaction
Common Stock
Options Exercise
- Transaction value
- $3,318,468
- Shares
- +57,294
- Change %
- +58%
- Price
- $57.92
- Shares after
- 156,893
- Date
- 27 Nov 2024
- Ownership
- Direct
GILD
transaction
Common Stock
Options Exercise
- Transaction value
- $5,761,220
- Shares
- +88,119
- Change %
- +56%
- Price
- $65.38
- Shares after
- 245,012
- Date
- 27 Nov 2024
- Ownership
- Direct
GILD
transaction
Common Stock
Sale
- Transaction value
- $5,259,297
- Shares
- -57,294
- Change %
- -23%
- Price
- $91.79
- Shares after
- 187,718
- Date
- 27 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
GILD
transaction
Common Stock
Sale
- Transaction value
- $8,106,948
- Shares
- -88,119
- Change %
- -47%
- Price
- $92.00
- Shares after
- 99,599
- Date
- 27 Nov 2024
- Ownership
- Direct
GILD
transaction
Common Stock
Sale
- Transaction value
- $477,381
- Shares
- -5,200
- Change %
- -5.2%
- Price
- $91.80
- Shares after
- 94,399
- Date
- 27 Nov 2024
- Ownership
- Direct
- Footnotes
- F2
GILD
transaction
Common Stock
Sale
- Transaction value
- $293,679
- Shares
- -3,199
- Change %
- -3.4%
- Price
- $91.80
- Shares after
- 91,200
- Date
- 27 Nov 2024
- Ownership
- Direct
- Footnotes
- F3
GILD
transaction
Common Stock
Sale
- Transaction value
- $956,708
- Shares
- -10,399
- Change %
- -11%
- Price
- $92.00
- Shares after
- 80,801
- Date
- 27 Nov 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -57,294
- Change %
- -47%
- Price
- $0.000000
- Shares after
- 64,376
- Date
- 27 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 57,294
- Exercise price
- $57.92
- Footnotes
- F4
GILD
transaction
Derivative
Non-qualified Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -88,119
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 196
- Date
- 27 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 88,119
- Exercise price
- $65.38
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Footnote F2
Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Footnote F3
Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Footnote F4
The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.